ARMATA PHARMACEUTICALS, INC.: 10-Q/A filed 2015-04-15

Name: ARMATA PHARMACEUTICALS, INC.: 10-Q/A filed 2015-04-15
Creator: ARMATA PHARMACEUTICALS, INC.

What ARMATA PHARMACEUTICALS, INC. reported in its quarterly report amendment filed 2015-04-15 (fiscal Q3 2014): 32 published measures, 96 facts as tagged in accession 0001144204-15-023068.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form: 10-Q/A (quarterly report amendment)
Filed: 2015-04-15
Fiscal period: fiscal Q3 2014
Accession: 0001144204-15-023068 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARMATA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-09-30	31,929,000	USD
At 2013-12-31	41,213,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-09-30	25,901,000	USD
At 2013-12-31	63,131,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2014-09-30	4,368,000	USD
At 2013-12-31	-22,625,000	USD
At 2012-12-31	12,943,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-09-30	9,786,000	USD
At 2013-12-31	20,355,000	USD
At 2013-09-30	4,859,000	USD
At 2012-12-31	862,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	21,207,000	USD	92
2014-01-01 to 2014-09-30	23,773,000	USD	273
2013-01-01 to 2013-12-31	-64,583,000	USD	365
2013-07-01 to 2013-09-30	-48,753,000	USD	92
2013-01-01 to 2013-09-30	-65,041,000	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	1,197,000	USD	273
2013-01-01 to 2013-09-30	97,000	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-09-30	-361,342,000	USD
At 2013-12-31	-385,115,000	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	187,159,093	shares	92
2014-01-01 to 2014-09-30	184,445,172	shares	273
2013-07-01 to 2013-09-30	99,156,809	shares	92
2013-01-01 to 2013-09-30	85,688,356	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	315,990,084	shares	92
2014-01-01 to 2014-09-30	323,604,642	shares	273
2013-07-01 to 2013-09-30	99,156,809	shares	92
2013-01-01 to 2013-09-30	85,688,356	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	0.11	USD/shares	92
2014-04-01 to 2014-09-30	0.11	USD/shares	183
2014-01-01 to 2014-09-30	0.12	USD/shares	273
2013-07-01 to 2013-09-30	-0.49	USD/shares	92
2013-04-01 to 2013-09-30	-0.49	USD/shares	183
2013-01-01 to 2013-09-30	-0.76	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	0.07	USD/shares	92
2014-01-01 to 2014-09-30	0.07	USD/shares	273
2013-07-01 to 2013-09-30	-0.49	USD/shares	92
2013-01-01 to 2013-09-30	-0.76	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-09-30	1,283,000	USD
At 2013-12-31	145,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	714,000	USD	273
2013-01-01 to 2013-09-30	1,206,000	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	-5,231,000	USD	92
2014-01-01 to 2014-09-30	-11,513,000	USD	273
2013-07-01 to 2013-09-30	-2,341,000	USD	92
2013-01-01 to 2013-09-30	-9,798,000	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-09-30	10,261,000	USD
At 2013-12-31	20,660,000	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	0	USD	92
2014-01-01 to 2014-09-30	0	USD	273
2013-07-01 to 2013-09-30	9,000	USD	92
2013-01-01 to 2013-09-30	233,000	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-09-30	2,535,000	USD
At 2013-12-31	2,391,000	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2014-09-30	7,562,000	USD
At 2013-12-31	7,562,000	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2014-09-30	27,000	USD
At 2013-12-31	8,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	5,334,000	USD	92
2014-01-01 to 2014-09-30	11,821,000	USD	273
2013-07-01 to 2013-09-30	2,338,000	USD	92
2013-01-01 to 2013-09-30	10,131,000	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	1,793,000	USD	92
2014-01-01 to 2014-09-30	4,692,000	USD	273
2013-07-01 to 2013-09-30	1,123,000	USD	92
2013-01-01 to 2013-09-30	5,359,000	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-09-30	187,159,093	shares
At 2013-12-31	182,535,562	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-09-30	362,001,000	USD
At 2013-12-31	358,828,000	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2014-09-30	559,000	USD
At 2013-12-31	473,000	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2014-09-30	12,446,000	USD
At 2013-12-31	12,446,000	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2014-09-30	448,000	USD
At 2013-12-31	297,000	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	20,884,000	USD	92
2014-04-01 to 2014-09-30	20,884,000	USD	183
2014-01-01 to 2014-09-30	22,818,000	USD	273
2013-07-01 to 2013-09-30	-49,039,000	USD	92
2013-04-01 to 2013-09-30	-49,039,000	USD	183
2013-01-01 to 2013-09-30	-65,430,000	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	1,701,000	USD	92
2014-01-01 to 2014-09-30	5,289,000	USD	273
2013-07-01 to 2013-09-30	1,215,000	USD	92
2013-01-01 to 2013-09-30	4,772,000	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	59,000	USD	273
2013-01-01 to 2013-09-30	66,000	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	23,000	USD	273
2013-01-01 to 2013-09-30	23,000	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2014-07-01 to 2014-09-30	26,438,000	USD	92
2014-01-01 to 2014-09-30	35,286,000	USD	273
2013-07-01 to 2013-09-30	-46,412,000	USD	92
2013-01-01 to 2013-09-30	-55,243,000	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	19,000	USD	273
2013-01-01 to 2013-09-30	125,000	USD	273

Inspect the source

Entity: ARMATA PHARMACEUTICALS, INC. / CIK 0000921114
Captured: 2026-09-20T05:08:00.156Z
SEC response SHA-256: e2bc0c6fd82f16eeba84a16462f0828ac4ed107fd97a134be631976d00a341c5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000921114.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))